TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06604832
Drug: saline solution (placebo)
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: As a placebo treatment, saline solution will be injected on the right side of the glabellar lines and forehead region instead of an active neuromodulator. The saline solution has no therapeutic effect and is used as a control to compare the results against the active treatment.
Study: NCT06610643
Drug: combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A combination of 5-day remdesivir and 10-day Nirmatrelvir/Ritonavir
Study: NCT06612476
Drug: Interleukin 6-guided antibiotic therapy
Normalized name: interleukin-6
DrugBank: Human interleukin-6 (DB15060)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Interleukin-6 group, antibiotic prescription decisions will made according to the results of IL-6.
Study: NCT06612476
Drug: GOLD-guided antibiotic therapy
DrugBank: Gold (DB14154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In guideline group, antibiotic prescription decisions will made according to the recommendations of GOLD guideline.
Study: NCT05846646
Drug: Immune checkpoint inhibitor
Normalized name: Anti-tim3 checkpoint inhibitor mbg453
DrugBank: Sabatolimab (DB16322)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1st infusion on Cycle 1 Day 2, and then thereafter as per product label
Study: NCT03250923
Drug: silver citrate complex and acemannan
DrugBank: Silver nitrate (DB11080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral rinse solution with each dose containing 100μg silver citrate complex and 40mg acemannan
Study: NCT04610138
Drug: CNM-ZnAg
Normalized name: CNM-Au8
DrugBank: CNM-Au8 (DB17952)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZnAg liquid solution
Study: NCT06241547
Drug: antimetic drugs（ dexamethasone，ondansetron）
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antimetic drugs (dexamethasone ondansetron) are used to prevent postoperative nausea and vomiting.
Study: NCT06153342
Drug: TL-925
Normalized name: Thallous chloride Tl 201
DrugBank: Thallous chloride Tl-201 (DB16624)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TL-925 is an eye drop.
Study: NCT05401006
Drug: Acitretin 25Mg Cap
Normalized name: ACITRETIN 25MG CAP
DrugBank: Acitretin (DB00459)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acitretin is an oral retinoid (a derivative of vitamin A) given in a dose 0.25-1 mg /kg/day for 3months in psoriatic patients
Study: NCT06527651
Drug: Genicular blocks (dexamethazone and lidocaine)
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Genicular blocks were applied bilaterally by another physiatrist who was experienced in ultrasonographic (US) interventional procedures more than 5 years. Total of 6mL solution consisting of 0.5 mg/2mL dexamethazone and 4mL %1 lidocaine for three branches of genicular nerves (superomedial, superolateral and inferomedial branches) was divided into three branches for each knee. Total of 12 mL solution was applied for each patient.
Study: NCT00092924
Drug: TRAIL-R1 mAb (TRM-1;HGS-ETR1)
Normalized name: Mane 'N Tail Mineral Ice
DrugBank: Mapatumumab (DB18945)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05581823
Drug: Tavapadon
Normalized name: Tavapadon
DrugBank: Tavapadon (DB14899)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets
Study: NCT05581823
Drug: Carbamazepine
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extended-release oral tablets
Study: NCT05710146
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 injection of 15mg/kg of TXA in 100mL of normal saline
Study: NCT05351736
Drug: Lurasidone
Normalized name: Lurasidone
DrugBank: Lurasidone (DB08815)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Treatment with lurasidone
Study: NCT04847206
Drug: 3,4-methylenedioxymethamphetamine
Normalized name: 3,4-Methylenedioxymethamphetamine
DrugBank: Midomafetamine (DB01454)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A moderate dose of 100 mg MDMA will be administered.
Study: NCT04847206
Drug: 3,4-methylenedioxyamphetamine
Normalized name: 3,4-methylenedioxyamphetamine
DrugBank: Tenamfetamine (DB01509)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A moderate dose of 93.9 mg MDA will be administered.
Study: NCT04826484
Drug: Exparel 133 miligrams per 10 milliliter injection
Normalized name: bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local wound infiltration with Exparel 133 miligrams per 10 milliliter injection
Study: NCT04826484
Drug: Bupivacaine Hydrochloride
Normalized name: Bupivacaine Hydrochloride
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local wound infiltration with 0.25% bupivacaine.
Study: NCT04762199
Drug: Osimertinib
Normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT05334316
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered intravenously or orally based on daily CRP values and CRP corticosteriod dosing algorithm
Study: NCT05498766
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive intravenous infusion of 130 mg/m² oxaliplatin on the first day of treatment cycle.
Study: NCT05127564
Drug: Diroximel fumarate
Normalized name: Diroximel fumarate
DrugBank: Diroximel fumarate (DB14783)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered as specified in the treatment arm
Study: NCT06523959
Drug: Apixaban 2.5 MG
Normalized name: apixaban 2.5 MG
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: To evaluate the benefits and risks of thromboprophylaxis with oral factor Xa inhibitor Apixaban compared to No anticoagulation
Study: NCT01882296
Drug: Pantoprazole_20
Normalized name: pantoprazole 20 MG
DrugBank: Pantoprazole (DB00213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pantoprazole 20mg for 7days administration
Study: NCT01882296
Drug: Pantoprazole_40
Normalized name: pantoprazole 40 MG
DrugBank: Pantoprazole (DB00213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pantoprazole 40mg for 7days administration
Study: NCT06398457
Drug: Darzalex Faspro (Daratumumab and hyaluronidase-fihj)
Normalized name: daratumumab-fihj / hyaluronidase-fihj Injection [Darzalex Faspro]
DrugBank: Hyaluronidase (human recombinant) (DB06205)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darzalex Faspro will be administered weekly as a subcutaneous injection on Days -42, -35, -28 and -21 (+/- 1 day) for a total of four doses at 1800 mg each.
Study: NCT05498766
Drug: Tegafur, Gimeracil and Oteracil Potassium
DrugBank: Oteracil (DB03209)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Participants will receive oral Tegafur, Gimeracil and Oteracil Potassium (40 mg/m², twice a day) for 2 weeks, followed by 1 week of rest.
Study: NCT05994131
Drug: Furmonertinib
Normalized name: Almonertinib
DrugBank: Almonertinib (DB16640)
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally taken once daily
Study: NCT06309823
Drug: MAS825
Normalized name: MAS825
DrugBank: MAS825 (DB16452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAS825 is a bi-specific IgG1 monoclonal antibody that simultaneously targets IL-1beta and IL-18, thereby neutralizing both cytokines that are thought to be integral to the pathogenesis of XLP-2.
Study: NCT05892705
Drug: Dexmedetomidine Injection [Precedex]
Normalized name: dexmedetomidine Injection [Precedex]
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intrathecal injection of 5 mcg dexmedetomidine
Study: NCT06010927
Drug: ketamine/midazolam
Normalized name: ketamine/midazolam/ondansetron
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: premedication
Study: NCT06010927
Drug: Ketofol
Normalized name: Ketozole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-extubation
Study: NCT04754815
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PD-L1 inhibitor administered as an intravenous (IV) infusion.
Study: NCT04754815
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Folate analog metabolic inhibitor administered as an intravenous (IV) infusion single agent chemotherapy for advanced NSCLC
Study: NCT04754815
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A novel antimicrotubular agent administered as an intravenous (IV) infusion single agent chemotherapy for advanced NSCLC
Study: NCT04754815
Drug: Nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Microtubule inhibitor administered as an intravenous (IV) infusion indicated for the treatment of locally advanced or metastatic NSCLC
Study: NCT05682547
Drug: 3% Diquafosol tetrasodium
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3% Diquafosol tetrasodium eye drops will be used to assess its usefulness in diabetic dry eye symptoms
Study: NCT04126044
Drug: PF-06439535 (CN)
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is the test drug Pfizer biosimilar of bevacizumab-EU.
Study: NCT04126044
Drug: bevacizumab - EU
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: This is the reference drug bevacizumab sourced from EU
Study: NCT03072667
Drug: Omegaven
Normalized name: Omegaven
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omegaven™ will be initiated at 0.5 gm fat/kg of body weight per day (5cc/kg per day of Omegaven™) for 2 days. On day 3, the rate of Omegaven™ will be increased to 1g/kg (10cc/kg) per day and will remain at this level thereafter unless otherwise indicated.
Study: NCT04650542
Drug: HBI-3000
Normalized name: HBIG
DrugBank: Hepatitis B immune globulin (DB05276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: small molecule, multi-ion channel blocker
Study: NCT04650542
Drug: Paroxetine
Normalized name: Paroxetine
DrugBank: Paroxetine (DB00715)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: serotonin uptake inhibitor, CYP2D6 inhibitor
Study: NCT06203470
Drug: Botulinum Toxin-A
Normalized name: Botulinum toxin A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Botulinum Toxin-A (BoNT-A) is an injectable neuromodulator produced by Clostridium Botulinum, a Gram-positive bacillus that causes Botulism.
Study: NCT06203470
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: topical Calcineurin inhibitor
Study: NCT04646967
Drug: Bupivacain
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: See active comparator description
Study: NCT04646967
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: See active comparator description
Study: NCT06135844
Drug: Medical Grade Mineral Oil
Normalized name: Mineral Oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inert ingredients: Saturated hydrocarbons, with a purity and chemical structure that differs substantially from food-grade or technical-/industrial-grade mineral oils.
Study: NCT03870334
Drug: BT-11 880 mg
Normalized name: BTS
DrugBank: Pyruvic acid (DB00119)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral once daily tablet
Study: NCT05130827
Drug: Plinabulin
Normalized name: Plinabulin
DrugBank: Plinabulin (DB05992)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40mg flat dose IV infusion, infused over approximately 30 minutes starting between 1-3 hours after stem cell infusion on day 0.
Study: NCT04546633
Drug: Coartem
Normalized name: Coartem
DrugBank: Artemether (DB06697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coartem® (dispersible tablets in blister pack) (for Cohorts 1 and 2), dose is based on body weight
Study: NCT05638880
Drug: Valsartan 80 mg
Normalized name: valsartan 80 MG
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Valsartan is an angiotensin receptor blocker.
Study: NCT05638880
Drug: Empagliflozin 10 MG
Normalized name: empagliflozin 10 MG
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Empagliflozin is an oral hypoglycemic drug.
Study: NCT05638880
Drug: Levocetirizine
Normalized name: Levocetirizine
DrugBank: Levocetirizine (DB06282)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levocetirizine, Histamine-1 receptor antagonists provide a highly successful approach for controlling allergic and inflammatory conditions
Study: NCT05528172
Drug: Ripasudil
Normalized name: ripasudil
DrugBank: Ripasudil (DB13165)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: K-321 ophthalmic solution
Study: NCT04868019
Drug: Fenofibrate Capsules
Normalized name: Fenofibrate Capsules
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Solutions will be prepared in the required strengths and labeled accordingly. Group A will receive Solution A i.e. Fenofibrate suspension is prepared by dissolving 200 mg capsule in 10 ml distilled water and given as a single dose of 10mg/kg (0.5 ml/kg) and Group B will receive solution B i.e. 0.5ml/ kg normal saline as a placebo. Both groups will receive LED phototherapy under standard conditions. The serum bilirubin level will be noted at the time of admission and then at 12hr, 24hr, and 48 hours of treatment
Study: NCT05253287
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH therapy will be initiated at a low dose of 2U/day and titrated slowly based on IGF-1 levels) subcutaneously for 1 year.
Study: NCT05625724
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Experimental drug administrated orally
Study: NCT05986981
Drug: Vaccine
Normalized name: VACCINES
DrugBank: Lyme disease vaccine (recombinant OspA) (DB00045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-escalation trial, according to the classic 3+3 model, divided into three dose levels of 0.5 mg, 1.0 mg, 2.0 mg for enrollment, is expected to enroll a total of 9-18 subjects (0.5 mg dose group to be enrolled in 3-6 subjects, 1.0 mg dose group is proposed to be enrolled in 3-6 subjects, 2.0 mg dose group is proposed to be enrolled in 3-6 subjects, and the dose group is proposed to be enrolled in 3-6 subjects, and the dose group is proposed to be enrolled in 3-6 subjects. dose group is proposed to include 3-6 subjects).
Study: NCT05054803
Drug: WJ-MSC (XCEL-UMC-BETA)
Normalized name: Allogeneic bone marrow-derived mesenchymal stromal cells (MSCs)
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of 2 Intrathecal infusions of WJ-MSC at day 1 and at 3 months
Study: NCT05290948
Drug: intravitreal injection of bevacizumab with acetazolamide tablets
Normalized name: acetazolamide Injection
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: intravitreal injection of bevacizumab with acetazolamide tablets
Study: NCT05290948
Drug: intravitreal injection of bevacizumab
Normalized name: bevacizumab Injection
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: intravitreal injection of bevacizumab
Study: NCT06233604
Drug: 0.9%sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: unilateral administration of 20ml of 0,2% ropivacaine + 2ml 0.9% sodium chloride for the erector spine plane block
Study: NCT06233604
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: unilateral administration of 20ml of 0,2% ropivacaine with 4mg Dexamethasone for the erector spine plane block
Study: NCT06233604
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: unilateral administration of 20ml of 0,2% ropivacaine with 50ug Dexmedetomidine for the erector spine plane block
Study: NCT04218786
Drug: Colchicine
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The tablet will be given once daily for the span of the study
Study: NCT06612996
Drug: Tramadol
Normalized name: Tramadol
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous tramadol
Study: NCT06612996
Drug: Magnesium sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous magnesium sulphate
Study: NCT06612593
Drug: Cilostazol
Normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 tablets of 50 mg cilostazol will be received for 4 weeks, then the does will be 2 tablets of 100 mg cilostazol twice daily for 20 weeks
Study: NCT05479032
Drug: Amantadine
Normalized name: Amantadine
DrugBank: Amantadine (DB00915)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2x100 mg Amantadine for 3-5 days (dosage can be doubled in case of missing response to treatment after 48 hours)
Study: NCT05624151
Drug: Dexmedetomidine +Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: infraorbital nerve block by dexmedetomidine plus bupivacaine
Study: NCT05624151
Drug: Magnesium Sulfate + Bupivacaine
Normalized name: Magnesium Sulfate
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: infraorbital nerve block by magnesium sulphate plus bupivacaine
Study: NCT05624151
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: infraorbital nerve block by bupivacaine only
Study: NCT04861207
Drug: Cladribine
Normalized name: Cladribine
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The conditioning regimen used will be cladribine-based at a dose of 5 mg / m2 for 5 days (iv.) and total body irradiation at a total dose of 12 Gy in three fractions.
Study: NCT06298955
Drug: OMS906 study drug
Normalized name: ethanol
DrugBank: OMS906 (DB17722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OMS906 study drug repeat-dose 5mg/kg IV administration at 8-week intervals
Study: NCT05036980
Drug: Trans Sodium Crocetinate
Normalized name: trans-crocetin
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single IV bolus
Study: NCT04705818
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Durvalumab will be administered by intraveinous infusion (1120 mg) on day 1, every 3 weeks. Treatment by durvalumab will start on Day 22 (i.e., day 1 of cycle 2)
Study: NCT04705818
Drug: Tazemetostat
Normalized name: tazemetostat
DrugBank: Tazemetostat (DB12887)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tazemetostat will be administered per-os, twice daily (800 mg x 2), continuously. Treatment by tazemetostat will start on day 1 (of cycle1).
Study: NCT04893577
Drug: EDTA
Normalized name: EDTA
DrugBank: Edetic acid (DB00974)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will treat their cold sore with EDTA eye drops based upon their randomization.
Study: NCT04893577
Drug: Abreva
Normalized name: Abreva
DrugBank: Docosanol (DB00632)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will treat their cold sore with Abreva based upon their randomization
Study: NCT05172050
Drug: Raloxifene
Normalized name: Raloxifene
DrugBank: Raloxifene (DB00481)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Raloxifene was administered as 60 mg hard gelatine capsule(s) once a day. Starting from day 2 of treatment: one single capsule (plus one of placebo to guarantee the blinding) containing 60 mg raloxifene was administered in Group 1, and 2 capsules 60 mg each for a total of 120 mg in Group 2.
Study: NCT04676061
Drug: Norethindrone acetate (NTA)
Normalized name: Norethindrone
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: norethindrone acetate, 5 mg tablet, orally, once daily for 7 consecutive days, every 4 weeks
Study: NCT04583007
Drug: Lanadelumab 150 mg
Normalized name: Lanadelumab 150 mg/mL solution for injection
DrugBank: Lanadelumab (DB14597)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: TAK-743-6001: Participants will receive subcutaneous (SC) injection of lanadelumab at a dose of 150 milligrams (mg) at the same frequency (for every 2 weeks \[Q2W\] or for every 4 weeks \[Q4W\]) given at the completion of SPRING study until benefit-risk no longer favors the individual participant or an appropriate alternative therapy becomes available or lanadelumab 150 mg/ 1 milliliter (mL) becomes commercially available or the participants turns 12 years of age or participant chooses to discontinue treatment. For participants aged 6-12 years, a dose frequency may be modified based on a benefit-risk assessment and medical decision from the treating physician.
Study: NCT04583007
Drug: Lanadelumab 300 mg
Normalized name: lanadelumab 300 mg in 2 mL SUBCUTANEOUS SOLUTION [TAKHZYRO]
DrugBank: Lanadelumab (DB14597)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: TAK-743-5012: Participants will receive SC injection of lanadelumab in prefilled syringe at a dose of 300 mg, Q2W or Q4W if well controlled for 26 weeks across Study TAK-743-3001 and this (TAK-743-5012) program.
Study: NCT05416775
Drug: SHR-8068；Adebrelimab
DrugBank: Adebrelimab (DB16412)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-8068: Sterile Injection, 50mg/10mL, Intravenous Infusion Adebrelimab: injection, 600mg/12mL, intravenous infusion
Study: NCT05416775
Drug: SHR-8068；adebrelimab and platinum-based chemotherapy
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-8068: Intravenous Infusion Adebrelimab: injection, intravenous infusion Pemetrexed disodium for injection: , intravenous drip Paclitaxel for injection (albumin-bound): intravenous drip Paclitaxel injection: intravenous drip Carboplatin injection: intravenous drip Cisplatin injection: intravenous drip
Study: NCT05416775
Drug: Adebrelimab；platinum-based chemotherapy
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adebrelimab: intravenous infusion Pemetrexed disodium for injection: intravenous drip Paclitaxel for injection (albumin-bound): intravenous drip Paclitaxel injection: intravenous drip Carboplatin injection: intravenous drip Cisplatin injection: intravenous drip
Study: NCT06336356
Drug: Baxdrostat
Normalized name: Baxdrostat
DrugBank: Baxdrostat (DB19090)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baxdrostat will be administered orally once daily.